CPP-B conjugate (mis-23D-B, mismatched PMO control)
Sequence: RXRRBRRXRRBRXB
PMO (morpholino antisense oligo)
| Experiment Id | EXP001213 |
|---|---|
| Paper | Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of |
| Peptide | CPP-B conjugate (mis-23D-B, mismatched PMO control) |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 12 mg/kg/day (PPMO dose) for 4 days |
| Mixing Ratio | |
| Formulation Format | covalent peptide–PMO conjugate (PPMO) |
| Formulation Components | CPP-B conjugated to mismatched PMO (mis-23D-B) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | mdx mouse (DMD model) / EGFP-654 (negative control for imaging) |
| Administration Route | intravenous (IV) |
| Output Type | negative control |
| Output Value | No exon 23-skipped transcript / no reporter upregulation (control). |
| Output Units | |
| Output Notes | Mismatched control reported as negative (no exon 23–skipped transcript in mdx; no EGFP upregulation in imaging control). |
| Toxicity Notes | |
| Curation Notes |